Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (PPBT) generates frequent news as a clinical-stage oncology company developing therapies that, according to its own reports, target tumor immune evasion and drug resistance. Investors and observers following PPBT news can track updates on its CAPTN-3 tri-specific antibody platform, the CEACAM1-blocking antibody CM24, and the dual IRS1/2 and STAT3 inhibitor NT219, as well as financing and listing developments.
Recent press releases highlight CAPTN-3 as a key source of news. The company has announced manufacturing milestones for IM1240, the first tri-specific antibody from the platform targeting 5T4, CD3 and NKG2A, including achievement of a commercially viable yield. Additional updates describe non-human primate toxicology data for IM1240, with Purple Biotech reporting an expanded therapeutic window compared with a non-capped comparator and a pharmacokinetic profile characterized by increased systemic exposure and prolonged half-life in that study.
News flow also covers preclinical data presentations at scientific meetings such as the ESMO Immuno-Oncology Congress and other conferences. These releases describe anti-tumor activity of IM1240 and IM1305 in models resistant to prior PD-1 therapy, transcriptomic analyses supporting the inclusion of an NKG2A arm, and ex vivo results in patient-derived tumor biopsies. Such items provide context on how the company positions CAPTN-3 within immuno-oncology research.
Beyond CAPTN-3, Purple Biotech issues updates on CM24 Phase 2 data in pancreatic ductal adenocarcinoma and on NT219, including an intention to grant a European patent for NT219 combination regimens and progress of a Phase 2 study in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Financial and corporate news includes quarterly results, public offerings of American Depositary Shares and warrants, at-the-market offering agreements, and Nasdaq minimum bid price notifications.
Readers who monitor PPBT news can use this page to follow scientific milestones, regulatory and clinical progress, capital-raising transactions, and listing-related announcements directly sourced from company press releases and SEC-furnished documents.
Purple Biotech (NASDAQ: PPBT) reported that its tri-specific antibody IM1240 from the CAPTN-3 platform completed a non-human primate toxicology study showing an expanded therapeutic window.
Key findings: IM1240 was tolerated at doses up to 300-fold higher than a non-capped comparator (IM1222) with significantly reduced immune-related toxicity and only modest cytokine release. IM1240 also showed a favorable PK profile with increased systemic exposure, dose-proportional AUC and Cmax, and a prolonged circulating half-life attributed to albumin incorporation and capping design. Efficacy in tumor-bearing mice occurred at exposures below those in the Study. The company plans regulatory submission toward first-in-human studies in H2 2026.
Purple Biotech (NASDAQ: PPBT) reported positive preclinical results for its CAPTN-3 tri-specific antibody platform presented at ESMO IO 2025. Two candidates, IM1240 (capped-CD3×5T4×NKG2A) and IM1305 (capped-CD3×TROP2×NKG2A), showed strong anti-tumor activity across multiple solid-tumor models, including activity in PD-1–resistant ex-vivo NSCLC and HNSCC samples. Transcriptomic analysis of ~11,000 TCGA samples supported co-expression of NKG2A with 5T4, justifying the NKG2A arm. IM1305 bound TROP2 and NKG2A (EC50 ~2 nM), showed PBMC-mediated killing at EC50 1–5 pM, and induced sustained tumor regression in humanized TNBC mice (p < 0.0001). Company expects IND-enabling progress and key milestones in 2026.
Purple Biotech (NASDAQ: PPBT) will present new preclinical data from its CAPTN-3 conditionally activated tri-specific antibody platform at ESMO-IO 2025 in London on December 10, 2025. The poster (FPN# 287P) led by Dr. Hadas Reuveni highlights two novel CAPTN-3 platform compounds and preclinical anti-tumor activity, including data in multiple PD-1 resistant models and evidence of engagement of T cells and NK cells against tumor-associated antigens. Management said the findings demonstrate platform versatility and synergy in treatment-resistant cancers. The poster will be posted in the company's Publications section after the congress.
Purple Biotech (NASDAQ: PPBT) reported Q3 2025 results and a business update on Nov 14, 2025. Key financials: $10.5M cash and short-term deposits as of Sept 30, 2025, with an expected cash runway into the first half of 2027. Q3 operating loss was $1.4M and adjusted operating loss $1.3M. R&D expenses declined to $0.6M (56% decrease YoY) largely from reduced CM24 Phase 2 costs.
Clinical and pipeline highlights: IM1240 achieved a commercially viable manufacturing yield and is being advanced toward an IND and Phase 1 initiation in 2026. IM1305 was nominated as a second CAPTN-3 tri-specific candidate targeting TROP2. NT219 Phase 2 and CM24 biomarker-driven plans continue.
Purple Biotech (NASDAQ: PPBT) announced a manufacturing milestone for IM1240, a CAPTN-3 tri-specific antibody targeting 5T4, CD3 and NKG2A. The company reports achieving a commercially viable yield and high-purity process for IM1240, validating CAPTN-3's scalability for complex tri-specific antibodies. IM1240 includes a protease-cleavable, albumin-bound cap intended to limit systemic CD3 activation and extend half-life, concentrating activity in the tumor microenvironment. The program is advancing toward first-in-human studies with an IND submission planned for 2026.
Purple Biotech (NASDAQ/TASE: PPBT) received a Nasdaq notice on Oct 16, 2025 that its American Depositary Shares closed below the required $1.00 minimum for 30 consecutive trading days. Under Nasdaq Listing Rule 5810(c)(3)(A) the company has a 180‑day cure period until April 14, 2026 to regain compliance by achieving a closing bid ≥ $1.00 for ten consecutive business days. The notice does not affect the current Nasdaq listing or trading of ADSs, nor its Tel Aviv listing. If noncompliant by April 14, 2026, Purple Biotech may be eligible for a second 180‑day period if it meets market‑value and other listing standards, or face delisting and the option to appeal. The company said it will monitor the ADS price and may consider options such as changing the ADS-to-ordinary share ratio to regain compliance.
Purple Biotech (NASDAQ/TASE: PPBT) has received an intention to grant from the European Patent Office for a patent application covering NT219 combinations with immunotherapies and MEK inhibitors. The patent (Application No. 20168234.1) will protect combinations of NT219 with various immunotherapies including anti-PD-1, PD-L1, CTLA-4, and CD20 antibodies, designed to enhance treatment of resistant cancers.
The company is currently conducting a Phase 2 study evaluating NT219 in combination with either pembrolizumab or cetuximab for squamous cell carcinoma of the head and neck (SCCHN). Preclinical studies have demonstrated synergistic activity of NT219 with immunotherapy in suppressing refractory tumors across multiple indications. The patent protection extends through 2036.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company focused on oncology therapeutics, has closed its previously announced public offering. The offering includes 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, with each ADS representing 200 ordinary shares, at $1.00 per share.
The offering also includes short-term warrants to purchase up to 11,999,998 ADSs at an exercise price of $1.00 per ADS, exercisable immediately and expiring in 24 months. The initial gross proceeds total $6 million, with potential additional proceeds of $12 million if all warrants are exercised. H.C. Wainwright & Co. served as the exclusive placement agent.
The company plans to use the proceeds for developing its oncology therapeutic candidates and general working capital purposes.
Purple Biotech (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies for tumor treatment, has announced the pricing of a $6 million public offering with potential additional proceeds of up to $12 million through warrant exercises.
The offering consists of 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, priced at $1.00 per share. Each ADS represents 200 ordinary shares. Additionally, short-term warrants to purchase up to 11,999,998 ADSs at $1.00 per ADS will be issued, exercisable immediately and expiring in 24 months. The offering is expected to close around September 5, 2025.
H.C. Wainwright & Co. serves as the exclusive placement agent. Proceeds will fund oncology therapeutic candidates development and general corporate purposes.
Purple Biotech (NASDAQ/TASE: PPBT) has announced promising new data for its CAPTN-3 tri-specific antibody IM1240 in collaboration with Mount Sinai. The research, led by Dr. Amir Horowitz, demonstrated successful tumor cell death in treatment-resistant head and neck cancer biopsies.
Key findings show synergistic effects between NK and T cell engager arms of IM1240, and analysis of 26,000 human transcriptomes validates the antibody's design targeting 5T4 and NKG2A. The company plans to submit an IND application in 2026 for first-in-human clinical trials.
The research spans multiple resistant cancers including NSCLC, HNSCC, and bladder cancer. IM1240's unique design offers potentially safer checkpoint inhibition compared to existing therapies, particularly through its selective NKG2A targeting.
FAQ
What is the current stock price of Purple Biotech (PPBT)?
What is the market cap of Purple Biotech (PPBT)?
